ASCO 2017 | Lenalidomide maintenance – an active approach to treating MM?
Gareth Morgan
• 2 Jun 2017
Gareth John Morgan, MD, FRCP, FRCPath, PhD, from the Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, discusses the outcomes of the Myeloma XI trial (NCT01554852), a study comparing a standard chemotherapy regimen of cyclophosphamide, dexamethasone plus thalidomide with a newer regimen of cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib, in treating multiple myeloma (MM). The results, as described by Prof. Morgan, support the use of lenalidomide maintenance in the clinic as treatment for MM. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
